Navigation Links
Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review
Date:3/25/2008

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced it has achieved key milestones in the ongoing Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration. Significant progress has been made in several areas including the curation of new biomarker and toxicology content and the expansion of existing ontological classifications. These developments will advance the FDA towards its goal of rapidly identifying potential genomic 'fingerprints' that could be used to quickly and easily compare genomic data from submissions of drugs in the same class.

Under the terms of the CRADA, Ingenuity Systems and the FDA will expand Ingenuity's content and software solutions to facilitate the research and regulatory review of biomarker, pharmacogenomic, and toxicogenomic data. The collaboration directly relates to the FDA's need to develop better tools for the review of genomic data.

"We are making progress towards the goals outlined in the CRADA," commented Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics. "We are looking forward to this collaboration over the course of this year so our team can benefit from these tools and information available from them on relationships between drugs and potential mechanism of action and mechanism of toxicity."

"Our collaboration with the FDA was a natural partnership given Ingenuity's close alliance with the industry initiatives and healthcare goals laid out by the Critical Path Initiative," stated Ramon Felciano, Ph.D., CTO and Vice President, Research of Ingenuity Systems. "We are confident that we can leverage Ingenuity's unique capabilities to provide the FDA with a clearer understanding of the biological and chemical relationships embedded in the regulatory data."

About Ingenuity Systems(R)

Ingenuity Systems is a leading provider of inform
'/>"/>

SOURCE Ingenuity Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008
2. Video: TI unveils industrys first family of complete analog front ends for superior ultrasound systems
3. HealthMEDX Partners With Silverchair Learning Systems
4. Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship
5. Siemens Urological Systems Tap U.S. Market
6. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
7. MTM Study Reports Improved Quality and Economic Outcomes Using Medication Management Systems Assurance Pharmaceutical Care System(TM)
8. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
9. Texas Organization of Rural and Community Hospitals (TORCH) Awards Phoenix Health Systems Endorsed Vendor Status
10. Swiss Systems Biology Initiative announces Flagship Projects
11. Plexus Systems, Inc. Announces Participation at AM EXPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...5 /PRNewswire-FirstCall/ -- Lung cancer patients,w...s may fare better as a,result, according to data f...linical trial. Data from the trial, which involved... injection), will be presented at the 44th Annual,...gy (ASCO) in Chicago,Ill., May 30 -- June 3, 2008...
(Date:5/15/2008)...h the goal of tailoring cancer treatment for each ...edical Center today presented a study suggesting a...assess treatment efficacy for patients with metast...and sometimes months to determine if a particular ...at long to observe any significant radiographic ch...
(Date:5/15/2008)...coxib, the anti-inflammatory medication also known... and reduces a specific proliferation measurement ...a study from The University of Texas M. D. Anderso...nificance of COX-2 inhibition toward preventing lu...ing the disease. , The study is the first large ...
(Date:5/15/2008)... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharm...GTEC) ("Genesis" or,the "Company"), a U.S. pharmac...he People,s Republic of China, today announced its... 2008, the Company,s third quarter of its,fiscal y...r the quarter,with the U.S. Securities Exchange Co...
Breaking Medicine News(10 mins):Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12
...r Medco Health solutions Inc. claims that parents ...he drugs themselves. // The study examined the pre...ast year. The study also found that if one twin i...ly that the other would also take it than non-twin...
...cine that it says can ward off common allergies su...e by Cytos Biotechnology has been tested on humans...n the TB bug, reported the online edition of Daily...doubled in the past 20 years, with the condition a...
...ocacy group, Families USA, suggests that majority ... have at least one parent employed full-time//. An...be earning members. The group's executive directo...eve these are low-income people who don't work, wh...
...ple suffering a severe personality disorder are po...ealth Services are putting their best foot forward...959 Mental Health Act has indicated that chronical...stay in Mental Healthcare Hospitals, if their illn...
Other Medicine News:
(Date:5/15/2008)...tion Most Affected by Disease -, WAYNE, N.J. and ...--,Bayer HealthCare Pharmaceuticals, Inc. and Onyx...unced that Nexavar(R) (sorafenib) tablets,signific...R=0.68;,p-value=0.014) in patients in the Asia-Pac... (HCC), or primary liver cancer versus those,recei...
(Date:5/15/2008)...all/ -- Medivation, Inc.,(Nasdaq: MDVN ) today an...al,trial of its novel androgen receptor antagonist...on at the 44th American Society of Clinical Oncolo...itle: New Targeted Strategies for Patients with Pr... 2 at 11:30 a.m. Central Time Abstract title: "Ph...
(Date:5/15/2008)...eptable Tolerability Profile, with Low... LAKE, N.J., May 15 /- The investigat...389) demonstrated activity in a,heavily pretreated...static,breast cancer, according to results of a mu... suggests that eribulin mesylate has a manageable,...
(Date:5/15/2008)...stCall/ -- Schering-Plough,Corporation (NYSE: SGP...t of,chronic hepatitis C virus (HCV) infection, an...ies with PEGINTRON(TM) (peginterferon alfa-2b) and...as well as boceprevir, the,company,s investigation...at,the 39th annual Digestive Disease Week (DDW) me...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Breast cancer more aggressive among obese women 14374 1Breast cancer more aggressive among obese women 14374 2Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 1Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 2Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 3MannKind to Present at the Cowen and Company Healthcare Conference 14372 1Dont Prescribe Antibiotics for Adult Sinus Woes 14369 1Dont Prescribe Antibiotics for Adult Sinus Woes 14369 2Dont Prescribe Antibiotics for Adult Sinus Woes 14369 3Dont Prescribe Antibiotics for Adult Sinus Woes 14369 4
...RK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClo...ompany today,announced that a Phase III study of E...rapy) in patients with locally advanced,unresectab...s,primary endpoint of improving overall survival. ..., a cancer,center network sponsored by the Nationa...
...0 Shown to Be Well Tolerated and Potentially Suite...April 10, 2007 /PRNewswire-FirstCall/ --,Pharmacop...t of,novel small molecule therapeutics, today anno...inical trial of PS433540, the company,s,lead inter...nsion,and diabetic nephropathy. Data from the sing...
Other Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests.
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies.
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products: